市场调查报告书
商品编码
1470873
患者异质骨移植/PDX 模型市场:按类型、肿瘤类型、应用和最终用户 - 2024-2030 年全球预测Patient-Derived Xenograft/PDX Model Market by Type (Mice Models, Rat Models), Tumor Type (Gastrointestinal Tumor Models, Gynecological Tumor Models, Hematological Tumor Models), Application, End-User - Global Forecast 2024-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
患者来源的异质骨移植/PDX模型市场规模预计2023年为2.2226亿美元,2024年达到2.5351亿美元,2030年将成长至5.7499亿美元,预计复合年增长率为14.54%。
患者来源的异种移植模型(PDX)是一种前沿的癌症研究模型,将人类肿瘤组织和细胞直接移植到免疫力缺乏或人源化小鼠体内,以在体内生长和维持患者的肿瘤,成为一种药物开发工具。全球癌症发生率不断上升,增加了对有效治疗方法的需求,并增加了对研发活动的投资。然而,与获取患者组织样本相关的伦理和监管问题以及人类和小鼠之间的生理差异限制了患者来源的异种移植(PDX)模式的发展。此外,政府对癌症研究的资助增加以及分子表征技术的进步预计将在未来创造利润丰厚的机会。
主要市场统计 | |
---|---|
基准年[2023] | 2.2226亿美元 |
预测年份 [2024] | 25351万美元 |
预测年份 [2030] | 57499万美元 |
复合年增长率(%) | 14.54% |
小鼠模型广泛用于肿瘤学中以开发新的疗法。
小鼠模型是使用最广泛的 PDX 模型,因为它们体积小、易于操作且在基因上与人类相似。这些模型对肿瘤生物学的理解和肿瘤学新治疗方法的发展做出了重大贡献。另一方面,大鼠模型由于其体积大以及在外科手术、影像诊断和采样方面的优势,已成为小鼠 PDX 模型的有价值的替代品。此外,大鼠在模拟某些人类癌症类型(例如神经胶质瘤和肉瘤)时表现出更多样化的免疫反应和更高的保真度。
肿瘤类型:专注于妇科肿瘤模型,研究妇科癌症。
胃肠道 (GI) 肿瘤模型对于研究影响消化器官系统(例如大肠直肠癌、胃癌和胰腺癌)至关重要。这些模型可用于研究肿瘤发展和转移的潜在机制以及评估潜在的治疗方法。妇科肿瘤模型对于妇科癌症(包括卵巢、子宫内膜癌和子宫颈癌)的研究至关重要。血液肿瘤模型用于研究血液癌症,如白血病、淋巴瘤和多发性骨髓瘤。呼吸道肿瘤模型对于研究肺癌的病理和治疗方法至关重要。泌尿系统肿瘤模型对于研究泌尿器官系统癌症(例如膀胱癌、肾臟癌和前列腺癌)非常重要,它可以让研究人员了解疾病的发展并确定个人化的治疗策略。
应用:在基础癌症研究中越来越多地采用患者来源的异种移植(PDX)模型
患者来源的异质骨移植(PDX)模型在基础癌症研究中非常有价值,因为它们忠实地模拟了肿瘤环境和患者异质性。生物标记分析对于识别预测和预后标记以指导个别患者的治疗决策至关重要。 PDX 模型透过捕捉肿瘤生长和治疗反应的分子变化来实现全面的生物标记开发。临床前药物开发在很大程度上依赖 PDX 模型来评估临床实验药物的安全性、有效性和药物动力学特性。 PDX模型概括了人类癌症的复杂性和多样性,因此是进入临床试验前评估抗癌药物的首选。
最终用户:提高学术和研究机构中患者来源的异质骨移植的适用性
学术和研究机构主要促进癌症生物学、药效测试和个人化医疗开发的研究。这些机构使用 PDX 模型来识别新的治疗标靶并了解肿瘤进展的机制。委外研发机构(CRO) 使用 PDX 模型进行药物发现和研发,为製药和生物技术公司提供临床前和临床测试服务。 CRO 将这些模型应用于药物开发的各个阶段,包括标靶辨识/验证、先导药物最适化、药物动力学/动态(PK/PD) 测试和毒性评估。製药和生物技术公司正在采用 PDX 模型来支持其药物发现管道并满足个人化癌症治疗的需求。
区域洞察
由于政府的支持措施以及促进该领域进步的各种研究机构的存在,美洲的 PDX 市场高度发展。此外,该地区的生物技术公司在为药物发现和个人化医疗方法提供 PDX 服务方面具有巨大价值。在欧盟 (EU),欧盟资助的计划重点在于扩大成员国对 PDX 模型的使用。中东地区对 PDX 建模研究的兴趣与日俱增,各组织纷纷采取倡议,为临床前癌症模型开发开发专业知识和资源。在亚太地区,生物医学研究的投入带动了国内药厂PDX模型研究的激增。亚太地区的政府框架也支持促进 PDX 模型研究的倡议,为患者来源的异质骨移植/PDX 模型市场开发潜在平台。
FPNV定位矩阵
FPNV定位矩阵对于评估患者来源的异质骨移植/PDX模型市场至关重要。我们检视与业务策略和产品满意度相关的关键指标,以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估,供应商被分为四个成功程度不同的像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市场占有率分析
市场占有率分析是一种综合工具,可对患者异质骨移植/PDX 模型市场中供应商的现状进行深入而深入的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献,以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外,该分析还提供了对该行业竞争特征的宝贵见解,包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略,从而在市场上获得竞争优势。
1. 市场渗透率:提供有关主要企业所服务的市场的全面资讯。
2. 市场开拓:我们深入研究利润丰厚的新兴市场,并分析其在成熟细分市场的渗透率。
3. 市场多元化:提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。
4.竞争力评估与资讯:对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。
5. 产品开发与创新:提供对未来技术、研发活动和突破性产品开发的见解。
1.患者异质骨移植/PDX模型市场的市场规模和预测是多少?
2.在病患异质骨移植/PDX模型市场的预测期间内,有哪些产品、细分市场、应用和领域需要考虑投资?
3.人异质骨移植/PDX模型市场的技术趋势与法规结构是什么?
4.在病患异质骨移植/PDX模型市场中主要供应商的市场占有率是多少?
5. 进入病人源性异质骨移植/PDX模型市场的合适型态和策略手段是什么?
[197 Pages Report] The Patient-Derived Xenograft/PDX Model Market size was estimated at USD 222.26 million in 2023 and expected to reach USD 253.51 million in 2024, at a CAGR 14.54% to reach USD 574.99 million by 2030.
A Patient-Derived Xenograft (PDX) model is an advanced cancer research and drug development tool that directly transplants human tumor tissues or cells into immunodeficient or humanized mice, allowing for the growth and maintenance of the patient's tumor in a living organism. The increasing prevalence of cancer worldwide drives demand for effective therapies, leading to increased investment in research and development activities. However, ethical and regulatory concerns associated with acquiring patient tissue samples and discrepancies between human and mouse physiology restrain the growth of the patient-derived xenograft (PDX) mode. Furthermore, increasing government funding initiatives for cancer research and advancements in molecular characterization techniques are expected to create lucrative opportunities in the future.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 222.26 million |
Estimated Year [2024] | USD 253.51 million |
Forecast Year [2030] | USD 574.99 million |
CAGR (%) | 14.54% |
Type: Extensive use of mouse models in oncology to develop novel therapeutics
Mice models are the most widely used PDX models due to their properties such as small size, ease of handling, and genetic similarity to humans. These models contribute significantly to understanding tumor biology and developing novel therapeutic approaches in oncology. On the other hand, rat models have emerged as a valuable alternative to mice PDX models due to their larger size, which benefits surgical procedures, imaging, and sampling. Additionally, rats exhibit more diverse immune responses and higher fidelity in modeling certain human cancer types, such as glioma and sarcoma.
Tumor Type: Emphasis on gynecological tumor models to study gynecological cancers
Gastrointestinal (GI) tumor models are crucial to studying cancers that affect the digestive system, such as colorectal, gastric, and pancreatic cancer. These models aid in examining the underlying mechanisms of tumor development and metastasis and evaluating potential therapeutic options. Gynecological tumor models are essential for studying gynecological cancers, including ovarian, endometrial, and cervical cancer. Researchers employ hematological tumor models to study blood cancers, including leukemia, lymphoma, and multiple myeloma. Respiratory tumor models are vital for investigating lung cancer pathogenesis and treatment options. Urological tumor models, crucial for studying cancers of the urinary system such as bladder, kidney, and prostate cancer, aid researchers in comprehending disease development and identifying personalized treatment strategies.
Application: Increasing Patient-derived Xenograft (PDX) Model Adoption for basic cancer research
Patient-derived xenograft (PDX) models are highly valuable in basic cancer research as they closely mimic the tumor environment and patient heterogeneity. Biomarker analysis is essential for identifying predictive or prognostic markers that guide treatment decisions for individual patients. PDX models enable comprehensive biomarker development by capturing molecular changes during tumor growth and therapy response. Preclinical drug development relies heavily on PDX models to assess investigational therapies' safety, efficacy, and pharmacokinetic properties. They are a preferred choice for evaluating anticancer agents before entering clinical trials, as PDX models replicate the complexity and diversity of human cancers.
End-User: Rising applicability of patient-derived xenografts in academic and research institutes
Academic and research institutions primarily facilitate the study of cancer biology, drug efficacy testing, and personalized medicine development. These institutions use PDX models to identify novel therapeutic targets and understand tumor progression mechanisms. Contract Research Organizations (CROs) offer preclinical and clinical trial services for pharmaceutical and biotechnology companies using PDX models for drug discovery and development. CROs apply these models in various stages of drug development, including target identification/validation, lead optimization, pharmacokinetics/pharmacodynamics (PK/PD) studies, and toxicity evaluation. Pharmaceutical and biotechnology companies employ PDX models to support their drug discovery pipelines and address the demand for personalized oncology treatments.
Regional Insights
The patient-derived xenograft/PDX model market in the Americas is highly evolving due to supportive government initiatives and the presence of various research institutes that contribute to advancements in this field. Moreover, biotechnology companies in the region are significant in providing PDX services for drug discovery and personalized medicine approaches. In the European Union, EU-funded projects focus on expanding access to PDX models across member countries. The Middle East is witnessing an increasing interest in PDX model research, with initiatives led by organizations and fostering expertise and resources for preclinical cancer model development. Asia-Pacific region's investment in biomedical research has resulted in a surge of PDX model studies by domestic pharmaceutical companies. The government frameworks in the Asia-Pacific region also support initiatives that promote PDX model research, developing a potential platform for the patient-derived xenograft/PDX model market.
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Patient-Derived Xenograft/PDX Model Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Patient-Derived Xenograft/PDX Model Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Patient-Derived Xenograft/PDX Model Market, highlighting leading vendors and their innovative profiles. These include Abnova Corporation, Altogen Labs, Aragen Life Sciences Pvt. Ltd., Bioduro-Sundia, BioReperia AB, Champions Oncology, Inc., Creative Biolabs, Crown Bioscience, Envigo RMS, LLC, EPO Berlin-Buch GmbH, GemPhamatech LLC, Hera Biolabs, Hera BioLabs Inc., Inotiv, Inc., InSphero AG, LIDE Shanghai Biotech, Ltd., Merck KGaA, Oncodesign Services, Pharmatest Services Oy, TheraIndx Lifesciences Pvt. Ltd., Urosphere SAS, Vertiv Group Corp., WuXi AppTec Co., Ltd., and XENTECH.
Market Segmentation & Coverage
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
1. What is the market size and forecast of the Patient-Derived Xenograft/PDX Model Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Patient-Derived Xenograft/PDX Model Market?
3. What are the technology trends and regulatory frameworks in the Patient-Derived Xenograft/PDX Model Market?
4. What is the market share of the leading vendors in the Patient-Derived Xenograft/PDX Model Market?
5. Which modes and strategic moves are suitable for entering the Patient-Derived Xenograft/PDX Model Market?